To address this gap, Guo et al. (2017) assembled a panel of the most widely studied MPNST cell lines, which included both NF1-associated and sporadic (non-NF1) patient-derived MPNST lines, enabling drug sensitivities specific to NF1-deficient cells to be explored [113]. Here, NF1 is linked to malignant peripheral nerve sheath tumor.